There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Antibodies > Cetuximab > CEB-Y31

Anti-Cetuximab Antibodies (Non-Neutralizing)

  • Source
    Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.
  • Isotype
  • Specificity
    Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 3 years under sterile conditions after reconstitution.
Anti-Cetuximab Antibodies (Non-Neutralizing) (Cat. No. CEB-Y31) SDS-PAGE gel

Anti-Cetuximab Antibodies (Non-Neutralizing) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Anti-Cetuximab Antibodies (Non-Neutralizing)Anti-Cetuximab Antibodies (Non-Neutralizing) (Cat. No. CEB-Y31) ELISA bioactivity

Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31, 10% human serum) and then add biotinylated cetuximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 39 ng/mL.

Anti-Cetuximab Antibodies (Non-Neutralizing)Anti-Cetuximab Antibodies (Non-Neutralizing) (Cat. No. CEB-Y31) ELISA bioactivity

Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y31) to the cetuximab.

Anti-Cetuximab Antibodies (Non-Neutralizing)Anti-Cetuximab Antibodies (Non-Neutralizing) (Cat. No. CEB-Y31) ELISA bioactivity

Measured by its neutralizing ability in a functional ELISA. Immobilized cetuximab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Cetuximab Antibodies (Cat. No. CEB-Y31) and Biotinylated Human EGFRvIII (Cat. No. EGR-H82E0) with a inhibition rate of 0%.


Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y31) captured on CM5 chip via anti-mouse antibodies surface, can bind human cetuximab with an affinity constant of 0.421 nM.

  • Background
    Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

This web search service is supported by Google Inc.